Neo-adjuvant chemotherapy for breast cancer consensus and controversy.doc

 PAGE \* MERGEFORMAT 32 Neo-adjuvant chemotherapy for breast cancer consensus and controversy 【Abstract】 locally advanced breast cancer after neoadjuvant chemotherapy can improve the removal rate and to increase breast-conserving opportunities, for patients with operable breast cancer neoadjuvant chemotherapy and postoperative adjuvant chemotherapy for survival is similar to the neo-adjuvant chemotherapy to achieve pathological complete remission (pCR ) patients survival is significantly improved. Neoadjuvant anthracycline-containing chemotherapy should choose classes, such as postoperative adjuvant taxane chemotherapy effective programs, treatment for 4 to 6 cycles. In addition, the neo-adjuvant chemotherapy, there are still many differences and disputes, mainly low complete remission rate, no effect of preoperative evaluation of the exact methods, the lack of efficacy and survival prediction and monitoring tools can not be individual to choose a new adjuvant chemotherapy and so on. Even so, some clinical, pathological and molecular indicators for the choice of neoadjuvant chemotherapy to improve pCR rates, to improve the survival of certain guiding significance, peripheral detection and RNA, tissue microarray technique may be neo-adjuvant chemotherapy individual applied research orientation. Keywords: breast cancer Breast cancer, preoperative chemotherapy (preoperative chemotherapy) to carry out in the 20th century, 70 years, Haagensen and Stout the first to propose a neo-adjuvant chemotherapy (neoadjuvant chemotherapy) to this concept, originally, as a non-surgical induction of locally advanced breast cancer chemotherapy (induced chemotherapy) or the initial chemotherapy (initial chemotherapy, primary chemotherapy), especially in 2001, NSABP B-18 large-scale randomized clinical study showed that preoperative chemotherapy and postoperative adjuvant chemotherapy for at least the same, and found that many of the original non-surgical pat